At a glance
| US product | Parsabiv |
|---|---|
| Target | Calcium-sensing receptor |
| Approved population | Adults on hemodialysis with secondary hyperparathyroidism |
| Administration setting | Dialysis care |
| Principal risk | Hypocalcemia |
Overview
Kidney failure can disrupt calcium, phosphate, and vitamin D balance and drive persistent parathyroid hormone release. Etelcalcetide addresses that hormonal response in patients already receiving hemodialysis. The approved product Parsabiv is administered through the dialysis setting rather than used as a general supplement or bone-repair injection. Trials show substantial reductions in parathyroid hormone and associated mineral changes. Those biochemical benefits should not be confused with established reductions in fractures or mortality. Its narrow labeled population matters: efficacy and safety are not established for primary hyperparathyroidism, parathyroid cancer, or chronic kidney disease in people who are not on hemodialysis.
How it works
Etelcalcetide interacts with the extracellular portion of the calcium-sensing receptor on parathyroid cells, increasing receptor activity. The gland consequently reduces parathyroid hormone secretion even without a rise in blood calcium. Lower PTH changes mineral movement between bone and blood, often lowering calcium further. The molecule is a peptide calcimimetic, distinct from oral small-molecule cinacalcet, although both work through the same receptor system.
A treatment tied to dialysis care
The US indication is secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis. Treatment is integrated with phosphate control, vitamin D management, and repeated mineral measurements. It is not an osteoporosis anabolic therapy: excessive suppression of PTH can reduce normal bone turnover and produce adynamic bone.
Supporting sources [1]
Biochemical outcomes in randomized trials
Placebo-controlled trials found greater PTH reductions with etelcalcetide over 26 weeks. A comparison with cinacalcet also evaluated PTH reduction and tolerability. These trials establish hormone-lowering activity in the studied dialysis population; they should not be summarized as proving prevention of cardiovascular events, fractures, or death.
Why calcium monitoring matters
Severe hypocalcemia can lead to tingling, cramps, seizures, QT prolongation, and ventricular arrhythmia. The label also describes worsening heart failure, gastrointestinal bleeding concerns, and low-turnover bone disease. Using another calcium-lowering treatment at the same time may increase risk, making medication reconciliation and laboratory follow-up clinically important.
Supporting sources [1]
Does lower PTH always mean better treatment?
No. The therapeutic goal is appropriate control of mineral and bone disorder, not maximal suppression of a laboratory number. Calcium, phosphate, PTH trajectory, symptoms, and other therapies must be interpreted together. Its dialysis-specific evidence does not establish benefit for an otherwise healthy person seeking stronger bones.
Supporting sources [1]
Reading this profile
Jurisdiction: United States; indications and availability vary by formulation and country.. Molecular class: Disulfide-linked synthetic calcimimetic peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Parsabiv — US prescribing information ↗Regulatory source · Checked 2026-10-27
- Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. ↗Original research · Checked 2026-10-27